Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay
Authors:
- Eleni Myrto TrifylliETEleni Myrto Trifylli
- Sotirios P. FortisSFSotirios P. Fortis
- Anastasios G. KriebardisAnastasios G. Kriebardis
- Nikolaos PapadopoulosNPNikolaos Papadopoulos
- Evangelos KoustasEvangelos Koustas
- Panagiotis SarantisPanagiotis Sarantis
- Spilios ManolakopoulosSMSpilios Manolakopoulos
- Melanie DeutschMDMelanie Deutsch
Open Access
- 30 June 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6333
Abstract
Hepatobiliary diseases, which include disorders of the liver, gallbladder, and bile ducts, remain a major global health concern. A significant proportion of deaths worldwide are attributed to hepatic diseases, accounting for 4% of the total global mortality in 2023. Among benign hepatobiliary diseases, metabolic dysfunction-associated steatotic liver disease is the most prevalent liver pathology, with a concerning rise in incidence, while it is recognized as the leading cause of liver transplantation in the United States. However, there is a notable rise over time in cases of autoimmune hepatobiliary disorders, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Meanwhile, hepatocellular carcinoma still remains the most frequently diagnosed hepatobiliary malignancy, constituting the third leading cause of malignancy-related mortality globally. Meanwhile, cholangiocarcinoma and gallbladder cancer are the second and third most common hepatobiliary malignancies, respectively, both exhibiting highly aggressive malignant behavior. Despite the notable advances in biomarkers and the development of therapeutic tools, early diagnosis and monitoring are considered pivotal for the management of the aforementioned pathologies. The development of new non-invasive biomarkers that can effectively identify, monitor these pathologies, and guide their management is considered a necessity. Extracellular vesicles (EVs) constitute nanoparticles with several embedded cargoes, with a significant role in intercellular communication, which are considered promising biomarkers in several diseases, including viral, metabolic, autoimmune, and malignant diseases. In this review, we will shed light on the role of EVs as novel frontiers in hepatobiliary diseases.Keywords
This publication has 136 references indexed in Scilit:
- Iron overload is closely associated with metabolic dysfunction‐associated fatty liver disease in type 2 diabetesObesity, 2025
- Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver DiseaseJAMA Network Open, 2024
- Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic HepatitisHepatology, 2020
- Dysregulated Autophagy and Lysosome Function Are Linked to Exosome Production by Micro‐RNA 155 in Alcoholic Liver DiseaseHepatology, 2019
- Platelets and Platelet‐Derived Extracellular Vesicles in Liver Physiology and DiseaseHepatology Communications, 2019
- Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR‐23a‐3p and Up‐regulate Programmed Death Ligand 1 Expression in MacrophagesHepatology, 2019
- Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLDJournal of Leukocyte Biology, 2018
- Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90Hepatology, 2017
- Extracellular vesicles carry microRNA‐195 to intrahepatic cholangiocarcinoma and improve survival in a rat modelHepatology, 2016
- Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cellsHepatology, 2014